Connect with us


The Endocannabinoid System and the Parasympathetic Nervous System



The autonomic nervous system is divided into two main facets: the sympathetic and the parasympathetic.

These two elements form an important piece of the puzzle that allows us to regulate our involuntary physiological functions – such as the beating of your heart, the movement of blood through your bloodstream, breathing, swallowing, etc.

As it turns out, and as we will see below, the endocannabinoid system is powerfully linked to the functionality of the parasympathetic nervous system.

Understanding the Parasympathetic Nervous System

One way to understand this interesting division in the autonomic nervous system is by the nicknames involved. While the sympathetic nervous system is referred to as our “fight or flight” system, the parasympathetic nervous system is far less dramatic in nature, and often referred to as “rest and digest”.

The parasympathetic nervous system is involved mostly in regulatory functionality. When you are not involved in any kind of crisis, most of what you’re doing in terms of your involuntary physiological functions is being governed by the central scripts involved in management of the parasympathetic nervous system.

It governs all the things that are necessary for you to get by as a functional system – salivation, tear production, digestion, and waste production.

In fact, the parasympathetic nervous system works hand in hand with the sympathetic nervous system – one governing functions when at rest or outside of a crisis, and the other taking over when some emergency is at hand.

You can see the hand of evolution in this relationship. Governing your basic functions should be efficient and of a long-term mind when there is no crisis about. You don’t want to over use your oxygen supply, your fuel, your hydration, or any other important resource when you don’t need to.

But when emergency strikes, it’s far more important to mobilize all of your resources for the most effective solution to resolve the crisis without existential risk.

These are two very different scenarios, and they demand very different scripts or protocols. Hence, evolution has equipped us with the best of both worlds.

The endocannabinoid system and the PSNS

The parasympathetic nervous system – also known as the PSNS – is the principle regulatory part of the nervous system. Hence, it should come as no surprise that the endocannabinoid system is an integral functional component.

As we have noted in previous discussions, the endocannabinoid system is a major part of the body’s basic regulatory functionality.

As such, the endocannabinoid system is a powerful supportive mechanism aiding in the basic work being accomplished on a moment to moment basis by the parasympathetic nervous system.

Importantly, the endocannabinoid system is integral to the maintenance of homeostasis, which implicates it in most of the processes being governed by the parasympathetic nervous system, including body temperature, blood sugar, and heart rate.

The CB1 receptors are found in the vagus nerve, which represents about three quarters of all parasympathetic neurons. Typically, these receptors are found in the output facet of the neuron rather than the input facet.

Given all of this, you can imagine how a deficiency in the endocannabinoid system may affect parasympathetic nervous system functionality. It’s not good.

Hence, by deduction, one can readily see that the introduction of factors that can maintain a lack of deficiency – or introduce a solution for an existing deficiency – may have a wide range of positive health benefits for all of the functions of this extremely diverse system that we call the parasympathetic nervous system.


CannTrust Holdings Inc (NYSE:CTST) Penetrates Into The United States After Investing $20 Million



CannTrust Holdings Inc (NYSE:CTST), a Canadian company that produces and sells medical and recreational marijuana has announced the expansion of its business into the United States.

The Canadian firm revealed that it signed a Letter of Intent through which it will start working with Elk Grove Farming Company, LLC to access more than 3,000 hemp production acres in California. The two companies struck a joint partnership that will allow CannTrust to secure a footing in the California market which is one of the biggest cannabis markets in the U.S.

“This agreement represents another bold move for CannTrust. Our U.S. operation is expected to deliver a significant increase in low-cost production capacity,” stated CannTrust CEO Peter Aceto.

CannTrust is financially ready to tap into the U.S market

The CannTrust CEO also noted that the company will take advantage of its experience in the formulation of standardized CBD products as part of its strategy to enter the U.S market. Mr. Aceto also revealed that his company’s successful equity offering provided enough financial muscle to fuel its ambitious expansion plans.

CannTrust aims to be among the leading and trusted suppliers of high-quality, standardized CBD formulations derived from hemp. The company believes that there will be an increasing demand for high-grade CBD formulations from international retailers. It therefore makes sense to invest in processes that will add value to the end product such as genetic studies and expert growing practices to achieve the highest safety and quality standards.

Elk Grove and CannTrust will each have 50% ownership in their joint operations. Elk Grove is an ideal partner for the endeavor because it has years of farming experience in a variety of products. Its focus includes products designed for crop protection, supply, and input. Its operations are distributed across California, which means that the groundwork has already been laid for the partnership. It will thus be easier for the CannTrust to penetrate into the California market.

Elk Grove executive Morgan Houchin stated that his company was excited about the partnership with CannTrust. He added that his firm’s experience in farming operations will be a great combination with CannTrust’s experience in creating class-leading formulations.

Continue Reading


Rocky Mountain High Brands Inc (OTCMKTS:RMHB) Strikes Broker Deal With Carlin Group



Lifestyle brand management firm Rocky Mountain High Brands Inc (OTCMKTS:RMHB) announced on Wednesday that it secured a broker deal with Carlin Group for its products in the retail space.

The broker agreement will allow Carlin to represent RMHB’s CBD-infused drinks through the HEMPd brand. It will also represent beverages infused with Hempseed extract under RMHB brands. The deal will also cover CBD-infused wellness products such as lotions, water-soluble solutions, capsules, gummies and tinctures as part of the HEMPd brand. Spirit Water will also be covered under the agreement.

The RMHB-Carlin broker deal covers multiple states. They include Missouri, Nebraska, Texas, South Dakota, North Dakota, Minnesota, Wisconsin, Illinois, Pennsylvania, Tennessee, Kentucky, Ohio, Indiana, and Michigan.

“We are very excited about the opportunity to have our entire product line represented by Carlin Group,” stated RMHB CEO Michael Welch.

The Carlin broker deal will boost RMHB’s exposure

Welch noted that the broker deal will strategically allow RMHB to leverage optimal exposure to mass marketers, grocery store chains, convenient stores, major retailers and other types of outlets. The company would not have managed to reach such a wide range of outlets cost-effectively without a broker deal.

The RMHB CEO also added that his company and Carlin will maintain a close collaboration so that they can facilitate retail availability of RMHB products. Welch also revealed that RMHB reviewed numerous other retail introduction options. This was before settling on Carlin which the company believes is the best-suited brand to rapidly get its products onto retail shelves.

Carlin Group’s Managing Director Albert Vergilio noted in a statement that his company was excited to host RMHB and the CBD-based products that are part of its HEMPd brand in Carlin’s new CBD division. He also added that it is part of investing in the future of CBD considering the fast-tracked popularity of CBD products, and the regulations that govern them.

Carlin’s sales team will undergo some training to get them acquainted with RMBH’s products. The sales team will then hold meetings with corporate customers as part of the retail rollout of the products. Sales that will be part of the broker deal are expected to kick off in Q3.

Continue Reading


Wildflower Brands Inc (OTCMKTS:WLDFF) Establishes Footprint Across The US With PO For Hemp CBD Products From Dillard’s Department Stores And Eyes Markets In Texas And Florida



Wildflower Brands Inc (OTCMKTS:WLDFF) has announced establishing a nationwide presence with a PO from Dillard’s Department store. The company has fulfilled the PO received from Dillard.

Hemp CBD products in 292 locations

Dillard’s department store will showcase the premium hemp CBD products of Wildflower in its 292 locations across the US. With its best practices and transparency, Wildflower is eyeing the key markets in Texas and Florida. The company will educate the customers in these regions about salable products. Wildflower has received subsequent orders from Dillard’s and is fulfilling the requirements.

Chief Executive Officer of Wildflower, William Maclean said the supply of CBD infused products to Dillard’s Department stores doubles the existing retail locations in the nation. The company aims to capitalize on its brand to become a household name. It will improve loyalty building because of the reputation and respect of Dillard’s as a retailer. Wildflower aims to provide health and wellness benefits of its CBD infused products to the customers in the US through Dillard’s.

Signs a deal with Highmark Interactive

Wildflower has signed a deal to use EQ – Brain Tracking, mobile software of Highmark Interactive, in the clinical research to study the functional neurological and cognitive effects of CBD. The company aims to get meaningful results and data that help to understand the functional and cognitive neurological properties of the cannabinoids.

William said the company would collect testimonials from the customers on its products that provide the health and wellness needs using plant-based solutions. The company will strive to improve the products, and the research helps it to reach that goal and growth with continued investments.

Acquires City Cannabis Corp

Wildflower has signed an LOI on April 3, 2019, to take over City Cannabis Corp. The company will issue its 60 million common shares for the takeover. The companies will complete the acquisition on receiving advice from corporate, tax, and securities law departments.

The cannabis retailer City Cannabis holds two licenses in the City of Vancouver to market cannabis. It is generating profits through operating dispensaries in Vancouver. The acquisition helps Wildflower to expand retail footprint using the expertise of City Cannabis.

Continue Reading

Trending Stories